Alvaro-Meca Alejandro, Berenguer Juan, Díaz Asunción, Micheloud Dariela, Aldámiz-Echevarría Teresa, Fanciulli Chiara, Resino Salvador
Unidad de Medicina Preventiva y Salud Pública, Facultad de Ciencias de la Salud, Universidad Rey Juan Carlos, Alcorcón, Madrid, Spain.
Unidad de Enfermedades Infecciosas/VIH, Hospital General Universitario Gregorio Marañón, Madrid, Spain.
PLoS One. 2017 Jun 15;12(6):e0179493. doi: 10.1371/journal.pone.0179493. eCollection 2017.
The incidence of stroke in human immunodeficiency virus (HIV)-infected individuals has been well analyzed in recent epidemiological studies. However, little is known about the specific contribution of hepatitis C virus (HCV) infection to stroke among HIV-infected individuals. The aims of this study were to analyze trends in the incidence rates of stroke in HIV-infected individuals during the combination antiretroviral (cART) era in Spain and to categorize them by the presence or absence of HCV coinfection. We analyzed hospital discharges with a diagnosis of stroke in Spain according to ICD-9-CM during 1997-2013. The study period was divided into four calendar periods (1997-1999, 2000-2003, 2004-2007, and 2008-2013). Patients were classified according to HCV serology. The number of HIV-infected patients was estimated based on data from the National Centre of Epidemiology. We calculated incidence rates (events per 10,000 patient-years) and in-hospital case fatality rates (CFR). The incidence of hemorrhagic stroke (HS) decreased in HIV-monoinfected patients (15.8 [1997-1999] to 6.5 [2008-2013]; P<0.001) and increased in HIV/HCV-coinfected patients (1.3 [1997-1999] to 5.5 [2008-2013]; P<0.001). The incidence of ischemic stroke (IS) decreased in HIV-monoinfected patients (27.4 [1997-1999] to 21.7 [2008-2013]; P = 0.005) and increased in HIV/HCV-coinfected patients (1.8 [1997-1999] to 11.9 [2008-2013]; P<0.001). The CFR was 3.3 times higher for HS than for IS for the whole study period. The CFR of HS in HIV-monoinfected patients decreased significantly (47.4% [1997-1999] to 30.6% [2008-2013]; P = 0.010) but did not change significantly among HIV/HCV-coinfected patients (41.4% [1997-1999] to 44.7% [2008-2013]; P = 0.784). The CFR of IS in the whole HIV-infected population decreased significantly (14.6% [1997-1999] to 10.9% [2008-2013]; P = 0.034), although no significant differences were found when each group was analyzed separately. In conclusion, after the introduction of cART, HS and IS rates decreased in HIV-monoinfected individuals, but increased steadily in HIV/HCV-coinfected individuals.
近期的流行病学研究对人类免疫缺陷病毒(HIV)感染者中风的发病率进行了充分分析。然而,关于丙型肝炎病毒(HCV)感染在HIV感染者中风发病中所起的具体作用,人们却知之甚少。本研究旨在分析西班牙联合抗逆转录病毒治疗(cART)时代HIV感染者中风发病率的变化趋势,并按是否合并HCV感染进行分类。我们根据国际疾病分类第九版临床修订本(ICD-9-CM)分析了1997年至2013年西班牙诊断为中风的住院病例。研究期分为四个日历时段(1997 - 1999年、2000 - 2003年、2004 - 2007年和2008 - 2013年)。患者根据HCV血清学进行分类。HIV感染患者的数量是根据国家流行病学中心的数据估算得出的。我们计算了发病率(每10000患者年的事件数)和院内病死率(CFR)。HIV单感染患者中出血性中风(HS)的发病率下降(从1997 - 1999年的15.8降至2008 - 2013年的6.5;P<0.001),而HIV/HCV合并感染患者中则上升(从1997 - 1999年的1.3升至2008 - 2013年的5.5;P<0.001)。HIV单感染患者中缺血性中风(IS)的发病率下降(从1997 - 1999年的27.4降至2008 - 2013年的21.7;P = 0.005),HIV/HCV合并感染患者中则上升(从1997 - 1999年的1.8升至2008 - 2013年的11.9;P<0.001)。在整个研究期间,HS的CFR是IS的3.3倍。HIV单感染患者中HS的CFR显著下降(从1997 - 1999年的47.4%降至2008 - 2013年的30.6%;P = 0.010),但HIV/HCV合并感染患者中无显著变化(从1997 - 1999年的41.4%升至2008 - 2013年的44.7%;P = 0.784)。整个HIV感染人群中IS的CFR显著下降(从1997 - 1999年的14.6%降至2008 - 2013年的10.9%;P = 0.034),不过对每组分别分析时未发现显著差异。总之,引入cART后,HIV单感染个体中HS和IS的发病率下降,但HIV/HCV合并感染个体中则稳步上升。